PR Newswire Clinical TrialsOriginal article
Bambusa Therapeutics Initiates Subcutaneous Dosing of BBT001 in Atopic Dermatitis, Following Compelling Intravenous Proof-of-Concept Data
Trial StartBBT001Positive
AI Analysis
Summary
Bambusa Therapeutics initiated subcutaneous dosing of BBT001, its bispecific antibody targeting IL-4Rα and IL-31, in atopic dermatitis patients, following positive intravenous proof-of-concept data. The expansion represents progression toward a more convenient delivery format for the long-acting candidate.
Clinical Trial Data
Outcome Details
First patient dosed in subcutaneous dosing following positive intravenous proof-of-concept data
Importance:6/10
Sentiment:
0.70
bispecific antibodyIL-4RαIL-31subcutaneous formulationproof-of-conceptatopic dermatitis
Read the original article
Published by PR Newswire Clinical Trials on October 1, 2026 1:00 PM